Q4 2025 Earnings Call Presentation February 9, 2026 Disclaimer Forward-Looking Statements & Non-GAAP Financial Measures: This presentation contains forward-looking statements regarding future results and events, including financial and operational guidance and projected estimates. For this purpose, any statements that are not statements of historical fact may be deemed forward-looking statements. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend," "outlook," and similar expres ...

Q2 2025 Financial Performance - Q2 2025 revenue reached $771 million, reflecting a 9% increase as reported and an 8% increase in constant currency[11] - Constant currency recurring revenue grew by 11%[11] - Constant currency instrument revenue grew by 4%[11] - Q2 2025 Non-GAAP EPS was $2.95, a 12% increase[11] - Waters division revenue grew by 10% in constant currency, while TA division revenue decreased by 6% in constant currency[33] Regional Performance (Constant Currency) - Asia experienced a 14% revenue growth, with China also at 14%[13] - Americas saw a 2% revenue growth[13] - Europe showed an 8% revenue growth[13] Full Year and Q3 2025 Guidance - The company projects full-year 2025 constant currency revenue growth between 5% and 7%[20] - The company projects Q3 2025 constant currency revenue growth between 4% and 7%[20] - Full-year 2025 Non-GAAP EPS is projected to be between $12.95 and $13.05[20] - Q3 2025 Non-GAAP EPS is projected to be between $3.15 and $3.25[20] Biosciences & Diagnostic Solutions Synergies - The company anticipates $200 million in cost synergies by year 3[26] - The company anticipates $290 million in revenue synergies by year 5[26]